103 related articles for article (PubMed ID: 28970072)
1. DNA interaction with platinum-based cytostatics revealed by DNA sequencing.
Smerkova K; Vaculovic T; Vaculovicova M; Kynicky J; Brtnicky M; Eckschlager T; Stiborova M; Hubalek J; Adam V
Anal Biochem; 2017 Dec; 539():22-28. PubMed ID: 28970072
[TBL] [Abstract][Full Text] [Related]
2. Glutathione modified CdTe quantum dots as a label for studying DNA interactions with platinum based cytostatics.
Ryvolova M; Smerkova K; Chomoucka J; Hubalek J; Adam V; Kizek R
Electrophoresis; 2013 Mar; 34(6):801-8. PubMed ID: 23400813
[TBL] [Abstract][Full Text] [Related]
3. Transcription inhibition by platinum-DNA cross-links in live mammalian cells.
Ang WH; Myint M; Lippard SJ
J Am Chem Soc; 2010 Jun; 132(21):7429-35. PubMed ID: 20443565
[TBL] [Abstract][Full Text] [Related]
4. Joint forces of mass spectrometric techniques (ICP-MS and MALDI-TOF-MS) and fluorescence spectrometry in the study of platinum-based cytostatic drugs interactions with metallothionein MT2 and MT3.
Pavelicova K; Do T; Vejvodova M; Vaculovic T; Nowak K; Matczuk M; Wu S; Krężel A; Adam V; Vaculovicova M
Talanta; 2024 Jul; 274():125920. PubMed ID: 38574532
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin.
Heudi O; Mercier-Jobard S; Cailleux A; Allain P
Biopharm Drug Dispos; 1999 Mar; 20(2):107-16. PubMed ID: 10206326
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
Malina J; Natile G; Brabec V
Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
[TBL] [Abstract][Full Text] [Related]
7. Raman spectroscopic evaluation of DNA adducts of a platinum containing anticancer drug.
Jangir DK; Mehrotra R
Spectrochim Acta A Mol Biomol Spectrosc; 2014 Sep; 130():386-9. PubMed ID: 24810023
[TBL] [Abstract][Full Text] [Related]
8. A shotgun approach for the identification of platinum-protein complexes.
Moraleja I; Moreno-Gordaliza E; Esteban-Fernández D; Mena ML; Linscheid MW; Gómez-Gómez MM
Anal Bioanal Chem; 2015 Mar; 407(9):2393-403. PubMed ID: 25618759
[TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A
Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094
[TBL] [Abstract][Full Text] [Related]
10. TCEP-based rSDS-PAGE AND nLC-ESI-LTQ-MS/MS for oxaliplatin metalloproteomic analysis.
Mena ML; Moreno-Gordaliza E; Gómez-Gómez MM
Talanta; 2013 Nov; 116():581-92. PubMed ID: 24148449
[TBL] [Abstract][Full Text] [Related]
11. Platinum anti-cancer drugs: Free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect.
Fong CW
Free Radic Biol Med; 2016 Jun; 95():216-29. PubMed ID: 27012421
[TBL] [Abstract][Full Text] [Related]
12. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
[TBL] [Abstract][Full Text] [Related]
13. Raman and Infrared Studies of Platinum-Based Drugs: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, and Heptaplatin.
Torres M; Khan S; Duplanty M; Lozano HC; Morris TJ; Nguyen T; Rostovtsev YV; DeYonker NJ; Mirsaleh-Kohan N
J Phys Chem A; 2018 Aug; 122(34):6934-6952. PubMed ID: 30071735
[TBL] [Abstract][Full Text] [Related]
14. Platinum based radiochemotherapies: Free radical mechanisms and radiotherapy sensitizers.
Fong CW
Free Radic Biol Med; 2016 Oct; 99():99-109. PubMed ID: 27417937
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
16. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.
Bassett E; Vaisman A; Havener JM; Masutani C; Hanaoka F; Chaney SG
Biochemistry; 2003 Dec; 42(48):14197-206. PubMed ID: 14640687
[TBL] [Abstract][Full Text] [Related]
17. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
18. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Stojanovska V; McQuade R; Rybalka E; Nurgali K
Curr Med Chem; 2017; 24(15):1520-1536. PubMed ID: 28079002
[TBL] [Abstract][Full Text] [Related]
20. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
Oprea A; Bazzazi H; Kangarloo B; Wolff JE
Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
